Open AccessDecitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
Author(s) -
Francesca Ferraro,
Agata Gruszczynska,
Marianna B. Ruzinova,
Christopher A. Miller,
Mary Elizabeth Percival,
Brian Uy,
Iskra Pusic,
Meagan A. Jacoby,
Mathew J. Christopher,
Miriam Kim,
Peter Westervelt,
Amanda F. Cashen,
Mark A. Schroeder,
John F. DiPersio,
Camille N. Abboud,
Lukas D. Wartman,
Feng Gao,
Daniel C. Link,
Timothy J. Ley,
John S. Welch
Publication year - 2022
Publication title -
haematologica
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.280153
Subject(s) - decitabine , myeloid leukemia , azacitidine , refractory (planetary science) , medicine , salvage therapy , induction therapy , cancer research , cytotoxic t cell , oncology , biology , chemotherapy , genetics , gene , dna methylation , gene expression , astrobiology , in vitro
Not available.